Novel Anti-cancer Agents and Their Mechanisms of Action
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 1633
Special Issue Editors
Interests: small-molecule drug discovery; medicinal chemistry; proteolysis-targeting chimeras (PROTACs); targeted protein degradation (TPD); chemical biology; CNS drug discovery
Special Issues, Collections and Topics in MDPI journals
Interests: small-molecule drug discovery; medicinal chemistry; proteolysis-targeting chimeras (PROTACs); targeted protein degradation (TPD); chemical biology; cheminformatics; synthetic organic chemistry
Special Issue Information
Dear Colleagues,
Despite social and technological progress, cancer remains a major concern and a leading cause of human suffering. Every year, there is an increase in the number of cases and deaths due to the ongoing danger posed by the majority of cancers. The alarming rise in incidence of new types of cancer and the public burden represents a real crisis for public health and healthcare systems worldwide. The comprehensive exploration of pathways responsible for, as well as mechanisms and structures of, anticancer chemical entities have significantly contributed in cancer prevention and treatment. The determination of different tumor cell lines, followed by the assessment of the impact of many natural and synthetic anticancer compounds, has resulted in remarkable success. However, major challenges remain, which in the current therapy is the toxicity may be attributed to the use of anticancer agents and the normal tissue damage caused as a consequence. There is a dire need to devise potential anticancer agents with fewer off-target effects. The scope of the present Issue includes novel anticancer compounds from synthetic and natural sources, validated in vitro or in vivo via assessments of their mechanism of actions, or new potential therapeutic strategies for cancer treatment such as proteolysis-targeting chimeras (PROTACs) and combinatorial chemotherapy. It is our pleasure to invite authors to submit original research articles and review articles focused on “Novel Anti-Cancer Agents and Their Mechanisms of Action”.
Dr. Chandra Bhushan Mishra
Dr. Mohd Abdullaha
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel anticancer agents
- mechanism of action
- synthetic and natural compounds
- PROTACs
- combinatorial chemotherapy
